These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

250 related items for PubMed ID: 412025

  • 1. [Continuous chrysotherapy of rheumatoid disease (evaluation of a retrospective study of 42 cases)].
    D'eshougues JR, Delcambre B, Maquerlot M, Defrance D.
    Lille Med; 1977; 22(7):430-8. PubMed ID: 412025
    [No Abstract] [Full Text] [Related]

  • 2. [Comparative analysis of the effectiveness and tolerance of chrysanol and myochrysine in patients with rheumatoid arthritis (preliminary report)].
    Slobodina GA.
    Ter Arkh; 1985; 57(7):131-6. PubMed ID: 2931846
    [Abstract] [Full Text] [Related]

  • 3. [Effectiveness and complications of chrysotherapy of rheumatoid arthritis].
    Erov NK.
    Revmatologiia (Mosk); 1986; (1):11-4. PubMed ID: 2940663
    [No Abstract] [Full Text] [Related]

  • 4. [Chrysotherapy and side effects (author's transl)].
    Eberl R.
    Wien Klin Wochenschr Suppl; 1974; 25():3-22. PubMed ID: 4279096
    [No Abstract] [Full Text] [Related]

  • 5. Efficacy and toxicity of retreatment with gold salts: a retrospective review of 25 cases.
    Sagransky DM, Greenwald RA.
    J Rheumatol; 1980; 7(4):474-8. PubMed ID: 6775078
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Chrysotherapy-induced aplastic anemia: a case report.
    Shearer CA, Parker WA.
    Am J Hosp Pharm; 1978 Sep; 35(9):1095-9. PubMed ID: 100010
    [Abstract] [Full Text] [Related]

  • 9. [Treatment of rheumatoid arthritis with gold preparations under control of their concentration in the blood serum].
    Beresten' TI, Trofimova TM.
    Ter Arkh; 1980 Sep; 52(2):102-6. PubMed ID: 7376087
    [No Abstract] [Full Text] [Related]

  • 10. [Treatment of rheumatoid arthritis with gold salts].
    Aranguena L, Hinojosa W, Chincaro C, Portugal J, Barrenechea O.
    Rev Clin Esp; 1980 Sep; 173(5-6):305-8. PubMed ID: 6238373
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Rheumatology. Side effects of chrysotherapy].
    Serre H, Sany J, Rosenberg F.
    Ann Med Interne (Paris); 1980 Sep; 127(8-9):552-9. PubMed ID: 137685
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Long-term chrysotherapy in rheumatoid arthritis.
    Srinivasan R, Miller BL, Paulus HE.
    Arthritis Rheum; 1979 Feb; 22(2):105-10. PubMed ID: 105739
    [Abstract] [Full Text] [Related]

  • 16. [Comparative effectiveness of chrysanol and auranofin in rheumatoid arthritis].
    Atakhodzhaeva ZA, Sigidin IaA.
    Ter Arkh; 1987 Feb; 59(12):30-3. PubMed ID: 3328906
    [Abstract] [Full Text] [Related]

  • 17. Experience and rationale of monitoring plasma levels of gold in rheumatoid arthritis.
    Lorber A.
    Agents Actions Suppl; 1981 Feb; 8():539-73. PubMed ID: 6781239
    [No Abstract] [Full Text] [Related]

  • 18. Chrysotherapy in rheumatoid arthritis with particular emphasis on the effect of chrysotherapy on radiographical changes and on the optimal time of initiation of therapy.
    Luukkainen R.
    Scand J Rheumatol Suppl; 1980 Feb; 34():1-56. PubMed ID: 6791272
    [No Abstract] [Full Text] [Related]

  • 19. Response of rheumatoid arthritis with leukopenia to gold salts.
    Gowans JD, Salami M.
    N Engl J Med; 1973 May 10; 288(19):1007-8. PubMed ID: 4633144
    [No Abstract] [Full Text] [Related]

  • 20. Near-cytotoxic gold salt therapy in long standing drug-refractory rheumatoid arthritis. A prospective investigation.
    de Bosset PL, Biter T.
    Schweiz Med Wochenschr; 1973 Aug 18; 103(33):1153-8. PubMed ID: 4201618
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.